University of Cincinnati Medical Center, Cincinnati, OH, U.S.A.
Division of Hematology/Oncology, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, U.S.A.
Curr Oncol. 2019 Aug;26(4):e433-e438. doi: 10.3747/co.26.4889. Epub 2019 Aug 1.
Gliomas are the most dreaded primary brain tumour because of their dismal cure rates. Ketogenic-type diets (kds) are high-fat, low-protein, and low-carbohydrate diets; the modified Atkins diet (mad) is a less-stringent version of a kd that still generates serum ketones in patients. The purpose of the present study was to retrospectively examine the feasibility of attaining ketosis and the safety of the mad in patients undergoing radiation and chemotherapy treatment for glioma. The rate of pseudoprogression (psp) after treatment was also assessed as a marker of radiation sensitization. To our knowledge, this dataset is the largest published relating to patients with glioma undergoing kd during radiation and chemotherapy.
We retrospectively studied 29 patients with grades ii-iv astrocytoma following the mad during standard radiation and chemotherapy. Feasibility of attaining ketosis was assessed though levels of beta hydroxybutyrate in blood. Pre- and post-radiation magnetic resonance images were evaluated for psp by a neuroradiologist blinded to patient data.
In the 29 patients who started the mad during radiation, ketosis was achieved in all 29 (100%). No serious adverse events occurred secondary to the mad. Of those 29 patients, 19 had glioblastoma multiforme. Of the latter 19 patients, 11 (58%) showed psp after mad and radiation and temozolomide therapy.
A modified Atkins diet is feasible and safe for glioma patients during radiation and chemotherapy treatment. The mad and resulting ketosis could play a role as a radiation sensitizer.
由于胶质瘤的治愈率较低,因此它是最令人恐惧的原发性脑肿瘤。生酮型饮食(KDs)是一种高脂肪、低碳水化合物、低蛋白的饮食;改良后的阿特金斯饮食(MAD)是一种不太严格的 KD,它仍能在患者中产生血清酮体。本研究的目的是回顾性地检查在接受放化疗治疗的脑胶质瘤患者中实现酮症的可行性和 MAD 的安全性。还评估了治疗后假性进展(PSP)的发生率,作为放射增敏的标志物。据我们所知,这是关于接受放化疗期间 KD 的脑胶质瘤患者的最大数据集。
我们回顾性研究了 29 名接受标准放化疗的 II-IV 级星形细胞瘤患者。通过血液中β-羟丁酸的水平评估酮症的可行性。由一位对患者数据不知情的神经放射科医生对放化疗前后的磁共振图像进行 PSP 评估。
在 29 名开始接受放化疗期间 MAD 的患者中,所有 29 名(100%)患者均实现了酮症。MAD 没有导致严重的不良反应。在这 29 名患者中,有 19 名患有多形性胶质母细胞瘤。在这 19 名患者中,有 11 名(58%)在 MAD 和放射治疗及替莫唑胺治疗后出现 PSP。
MAD 对接受放化疗的脑胶质瘤患者是可行且安全的。MAD 和由此产生的酮症可能作为放射增敏剂发挥作用。